{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:34:18Z","timestamp":1791092058653,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ygyno.2014.03.571","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T01:31:50Z","timestamp":1396575110000},"page":"433-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG\u2013PEI\u2013cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"133","clinical-trial-number":[{"clinical-trial-number":"nct01489371","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ronald D.","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"DeBernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner K.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.03.571_bb0005","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4161\/hv.20738","article-title":"Immunotherapy in ovarian cancer","volume":"8","author":"Mantia-Smaldone","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14712598.2011.566854","article-title":"Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature","volume":"11","author":"Whitworth","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0015","first-page":"1111","article-title":"Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12","volume":"60","author":"Duda","year":"2000","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ygyno.2014.03.571_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1479-5876-5-66","article-title":"Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease<1cm) associated with ovarian cancer or primary peritoneal carcinoma","volume":"12","author":"Lenzi","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2005.09.024","article-title":"Synthesis and application of biocompatible non-viral gene delivery system for immunogene therapy of cancer","volume":"109","author":"Fewell","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0030","first-page":"3304","article-title":"Use of interleukin-12 gene nanocomplexes as a general treatment against disseminated peritoneal malignancies","volume":"48","author":"Fewell","year":"2007","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jgm.1356","article-title":"Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally","volume":"11","author":"Fewell","year":"2009","journal-title":"J Gene Med"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/gt.2009.159","article-title":"Phase-I clinical trial of IL-12 plasmid\/lipopolymer complexes for the treatment of recurrent ovarian cancer","volume":"17","author":"Anwer","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2013.07.081","article-title":"Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer","volume":"131","author":"Anwer","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0050","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0055","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<720::AID-IJC10>3.0.CO;2-5","article-title":"Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin","volume":"77","author":"Zagozdzon","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0060","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1158\/1078-0432.CCR-06-2894","article-title":"Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect","volume":"13","author":"Zhu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0065","first-page":"1661","article-title":"Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma","volume":"3","author":"Teicher","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1479-5876-7-104","article-title":"Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18","volume":"7","author":"Alagkiozidis","year":"2009","journal-title":"J Transl Med"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/DDDT.S43184","article-title":"Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study","volume":"7","author":"Zarogoulidis","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2011.37.5394","article-title":"Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma","volume":"30","author":"Tarhini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0085","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.ygyno.2014.03.571_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00262-003-0391-x","article-title":"Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells","volume":"52","author":"Ujhazy","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ygyno.2014.03.571_rf0090","first-page":"3689","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2014.03.571_rf9000","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00262-003-0391-x","article-title":"Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells","volume":"52","author":"Ujhazy","year":"2003","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.ygyno.2014.03.571_bb0100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814008130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814008130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:34:47Z","timestamp":1758771287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814008130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0090825814008130"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.571","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG\u2013PEI\u2013cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}